Experimental Study

Immunooexpression of cyclin D1 in colorectal carcinomas is not correlated with survival outcome

Jaudah Al-Maghrabi a,b,d,*, Shagufta Mufti b, Wafaey Gomaa b,e, Abdelbaset Buhmeida d, Mohammed Al-Qahtani d, Mahmoud Al-Ahwal a,c

a Scientific Chair for Colorectal Cancer, King Abdulaziz University, Jeddah, Saudi Arabia
b Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia
c Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
d Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
e Department of Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt

ARTICLE INFO

Article history:
Received 20 December 2014
Accepted 2 January 2015
Available online 3 February 2015

Keywords:
Colorectal cancer
Immunohistochemistry
Cyclin D1
Prognosis
Survival

ABSTRACT

Background: Colon and colorectal cancer (CRC) research has entered a new era with recent updates of molecular events and prognostic markers. Among other prognostic markers, exaggerated expression of nuclear CCND1 has key role in tumour pathogenesis and metastases of CRC and has also been claimed to predict response to treatment.

Objectives: This study was designed to evaluate the prognostic and predictive value of CCND1 in CRC and the correlation of CCND1 expression with the different clinicopathological parameters.

Methods: Paraffin blocks from 117 primary CRC were retrieved from the archives of the Department of Pathology at King Abdulaziz University. Tissue microarrays were designed and constructed. The immunostaining of CCND1 was performed and analysed.

Results: There were more cases with low nuclear immunooexpression of CCND1 in both primary tumours and nodal metastasis (p<0.001). Cyclin D1 did not show association with clinicopathological features except with lymphovascular invasion. Low nuclear immunooexpression of CCND1 was associated with negative lymphovascular invasion (p=0.046). There was no statistically significant correlation between CCND1 immunooexpression and survival probability (Log Rank =2.474, p =0.116).

Conclusion: Our study indicates that CCND1 immunooexpression cannot be used as a predictor of survival in CRC. It also shows no significant correlation with clinicopathological features except with lymphovascular invasion.

© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All rights reserved.

1. Introduction

New advances in the molecular pathology of cancer over the past two decades described key signalling pathways involved in malignant progression of colorectal carcinoma (CRC). Upregulation of nuclear cyclin D1 (CCND1) plays an important role in pathogenesis and metastases of CRC [1,2]. High nuclear CCND1 expression occurs in one-third of CRC [3]. Sensitive biological markers are needed to maximise the benefit of therapeutic approaches in CRC [4]. Study of molecular events and prognostic factors is therefore important in CRC research. In CRC cell lines, CCND1 downregulation has anti-APC mutation effect in transgenic mice [5].

http://dx.doi.org/10.1016/j.jmau.2015.01.001
2213-879X/© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All rights reserved.
CCND1 interacts with other proteins such as DNA repair proteins [6,7]. Between CCND1a and CCND1b, only CCND1a transfer to nuclear chromatin sufficiently provokes DNA damage response (DDR) [6]. Reduction of endogenous CCND1 in CRC cells also reduces the DDR in response to 5-FU treatment [6].

Arrays of core biopsies obtained from paraffin-embedded tissues are called as tissue microarrays (TMAs). These arrays serve as an excellent means for high-throughput gene or protein expression analysis among population based large study groups of cancer patients on a single slide. This technology is increasingly being used for the high throughput analysis of the diagnostic, predictive, or prognostic value of biomarkers in tissue specimens. Immunohistochemical (IHC) methods seem to be most ideal for validation since the tissue based studies are present in the form of formalin fixed paraffin-embedded tissue blocks [8]. The principle of TMA is miniaturisation and a high throughput gene or protein expression analysis. TMA technology has been implicated widespread in cancer studies including CRC [9,10].

The aim of this study was to evaluate the prognostic and predictive value of cyclin D1 in colorectal carcinomas and the correlation of cyclin D1 expression with the different clinicopathological features in patients attending King Abdulaziz University Hospital from 1995 to 2012.

2. Materials and methods

2.1. Patients

The study included paraffin wax blocks of tumour from 117 patients with CRC and 29 corresponding to nodal metastases. Blocks were collected from the Department of Pathology at King Abdulaziz University, Jeddah, Saudi Arabia from 1995 to 2012. Patients’ demographic data is listed in Table 1. The study was approved by the Research Committee of the Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz University. Disease-free survival (DFS) was calculated as the time from diagnosis to the appearance of recurrent disease (or date last seen disease-free).

2.2. Tissue microarray (TMA) construction

TMAs were constructed as described by Kallioniemi [11]. New sections were prepared from the donor blocks and stained with haematoxylin–eosin (H&E). These slides were used to guide the samplings from morphologically representative regions of the tissues. TMA block was constructed using one punch from each colorectal carcinoma depending on the most cellular region of the tumour marked by a pathologist. A tissue arrayer (Tissue Micro Array Master 3D Histech, EU) was used to create TMAs.

2.3. Immunohistochemical staining

Immunostaining staining for the CCND1 to sections of the formalin-fixed colonic biopsies microarray was carried out. Four micrometre thick sections were prepared from paraffin blocks and mounted on positive charged slides. Sections were deparaffinised and rehydrated. Slides were immersed in H2O2 (0.3%) for 12 min to block the endogenous peroxidase activity. Slides were then pre-treated in microwave oven in 10 mM citrate buffer (pH 6) for three cycles of 5 min each. Immunostaining with CCND1 using Ventana “ready to use” kit was performed in an automated immunostainer (BenchMark XT, Ventana Medical Systems Inc., Tucson, AZ, USA) according to the instruction manual attached. Subsequently, sections were washed, counterstained with haematoxylin and mounted. Negative control (by substitution of primary antibody with Tris-buffered saline) was used. Positive control was used as those from breast cancer.

2.4. Scoring of immunohistochemistry

The intensity of the staining was graded as: 0, no staining; 1, mild staining; 2, moderate staining; and 3, marked staining. The percentage of staining was reported as: 0, less than 5%; 1, 5–25%; 2, 26–50%; 3, 51–75%; and 4, more than 75%. The final score was calculated by the sum of intensity and percentage as follow: 0, 0–1; 1, 2; 2, 3–5; 3, 6–7 [12]. For statistical purpose, CCND1 immunoscores were dichotomised as low expression (0 and 1), and high expression (2 and 3).

Table 1  
Clinicopathological parameters of CRC (n = 117) patients attending King Abdulaziz University Hospital, Jeddah.

| Parameter                      | Number (%) |
|--------------------------------|------------|
| Sex                            |            |
| Male                           | 59 (50.4%) |
| Female                         | 58 (49.6%) |
| Grade                          |            |
| Well-differentiated            | 32 (27.4%) |
| Moderately differentiated      | 70 (59.8%) |
| Poorly differentiated          | 15 (12.8%) |
| Age                            |            |
| <60 years                      | 58 (49.6%) |
| ≥60 years                      | 59 (50.4%) |
| Tumour location                |            |
| Right colon                    | 37 (31.6%) |
| Left colon                     | 71 (60.7%) |
| Rectum                         | 9 (7.7%)   |
| Tumour size                    |            |
| <5 cm                          | 51 (43.6%) |
| ≥5 cm                          | 66 (56.4%) |
| Primary tumour                 |            |
| T1                              | 2 (1.7%)   |
| T2                              | 21 (17.9%) |
| T3                              | 87 (74.4%) |
| T4                              | 7 (6%)     |
| Nodal metastasis               |            |
| Negative                       | 68 (58.1%) |
| Positive                       | 40 (34.9%) |
| Distant metastasis             |            |
| Negative                       | 86 (73.5%) |
| Positive                       | 31 (26.5%) |
| Lymphovascular invasion        |            |
| Negative                       | 104 (88.9%)|
| Positive                       | 13 (11.1%) |
| Margin status                  |            |
| Free                           | 112 (95.7%)|
| Involved                       | 5 (4.3%)   |
| Relapse                        |            |
| No relapse                     | 79 (67.5%) |
| Relapse                        | 38 (32.5%) |

T1: Tumour involves submucosa.  
T2: Tumour involves muscularis propria.  
T3: Tumour crosses through the muscularis propria into the subserosa or into non-peritonealised pericolic or perirectal tissues.  
T4: Tumour directly involves other organs/structures, and/or perforates visceral peritoneum.
Table 2
Categories of immunoexpression of CCND1 in primary CRC and nodal metastases among patients attending King Abdulaziz University Hospital, Jeddah.

|                  | Primary tumour (n = 117) | Nodal metastasis (n = 29) | p value |
|------------------|--------------------------|----------------------------|---------|
| Low expression   | 90 (76.9%)               | 20 (69%)                   | <0.001  |
| High expression  | 27 (23.1%)               | 9 (31%)                    | 0.34**  |

** One sample non-parametric chi-square test.
* Mann–Whitney test.

2.5. Statistical analysis

Differences between two groups of patients on one variable were tested by using Mann–Whitney test. To test association procedure in three groups of patients on one independent variable the Kruskal–Wallis test was used. Chi-square was used to test association between CCND1 expression and clinicopathological features. Multivariate analysis was used to predict nodal metastasis, distant metastasis, surgical resection margins, lymphovascular invasion, and recurrence in relation immunoexpression of cyclin D1. The Kaplan–Meier procedure was used to calculate the survival probabilities and the Log Rank test was used to compare the difference between survivals. The endpoint for patients was death from tumour (disease-free).

Table 3
Distribution of high CCND1 immunoexpression (n = 27) in relation to clinicopathological parameters among CRC patients attending King Abdulaziz University Hospital, Jeddah.

| Variable                  | Number (%) | p value |
|---------------------------|------------|---------|
| Grade                     |            |         |
| Well-differentated        | 10 (37%)   | 0.257*  |
| Moderately differentiated | 14 (51.9%) |         |
| Poorly differentiated     | 3 (11.1%)  |         |
| Sex                       |            |         |
| Male                      | 13 (48.1%) | 0.829** |
| Female                    | 14 (51.9%) |         |
| Age                       |            |         |
| ≥60 years                 | 15 (55.6%) | 0.517** |
| <60 years                 | 12 (44.4%) |         |
| Tumour location           |            |         |
| Right colon               | 5 (18.5%)  | 0.087*  |
| Left colon                | 19 (70.4%) |         |
| Rectum                    | 3 (11.1%)  |         |
| Tumour size               |            |         |
| <5 cm                     | 12 (40%)   | 0.545***|
| ≥5 cm                     | 15 (60%)   |         |
| Depth of invasion (pT)    |            |         |
| T1                        | 2 (7.4%)   | 0.441*  |
| T2                        | 5 (18.5%)  |         |
| T3                        | 18 (66.7%) |         |
| T4                        | 2 (7.4%)   |         |
| Nodal metastasis (n = 29) |            |         |
| Negative                  | 16 (59.3%) | 0.537** |
| Positive                  | 11 (40.7%) |         |
| Distant metastasis        |            |         |
| Negative                  | 22 (81.5%) | 0.269** |
| Positive                  | 5 (18.5%)  |         |
| Lymphovascular invasion   |            |         |
| Negative                  | 21 (77.8%) | 0.046** |
| Positive                  | 6 (22.2%)  |         |
| Margin status             |            |         |
| Free                      | 25 (92.6%) | 0.326** |
| Involved                  | 2 (7.4%)   |         |
| Relapse                   |            |         |
| Relapse                   | 20 (74.1%) | 0.268** |
| No relapse                | 7 (25.9%)  |         |

* Kruskal–Wallis test.
** Chi square test.

Table 4
Multivariate analysis for CCND1 immunoexpression among CRC patients attending King Abdulaziz University Hospital, Jeddah.

| Variable                  | Adjusted R square | p value |
|---------------------------|-------------------|---------|
| Nodal metastasis          | 0.006             | 0.552   |
| Distant metastasis        | 0.002             | 0.365   |
| Surgical resection margins| 0.000             | 0.322   |
| Lymphovascular invasion   | 0.036             | 0.025   |
| Recurrence                | 0.000             | 0.311   |

Disease-free survival (DFS) was calculated as the time from diagnosis to the appearance of recurrent disease (or date last seen disease-free). Statistical procedures were performed using SPSS® Release 16.0. Statistical significance was determined at p value of ≤0.05 and was 2-sided.

3. Results

In Table 2 we present the categories of immunoexpression in primary CRC and nodal metastases. Twenty-seven patients showed high CCND1 immunoexpression and its correlation to clinicopathological parameters is presented in Table 3. In Table 4 we present the multivariate analysis for CCND1 immunoexpression. Fig. 1 presents the CCND1 nuclear expression in CRC.
3.1. Immunohistochemistry of CCND1

There were more cases with low CCND1 immunostaining in both primary tumours and nodal metastasis ($p < 0.001$). There was no difference between CCND1 immunostaining in primary tumours and nodal metastasis.

3.2. Relation of CCND1 immunostaining to clinicopathological features and survival probability

CCND1 immunostaining did not show any association with clinicopathological features except with lymphovascular invasion. Low nuclear expression of CCND1 was associated with negative lymphovascular invasion ($p = 0.046$). There was also no relation between CCND1 immunostaining and survival probability (Log Rank = 2.474, $p = 0.116$) (Fig. 2).

4. Discussion

Colorectal carcinoma (CRC) is one of the most frequent cancers in the Western world and with the changes of life behaviours; CRC has reportedly become more and more frequent in China [12,13]. CRC is the third most common cancer in men and the second in women worldwide. Almost 55% of the cases occur in more developed regions [14]. According to the Saudi Arabian National Cancer Registry, CRC is accounting for 11.3% of all newly diagnosed cases in year 2009. This cancer ranked first among male population and third among female in Saudi population.

The pathogenesis and progression of CRC are results of multiple genetic alterations occurring in a systematic fashion. In the past decade research has identified multiple molecules regulating CRC in an effort to highlight biologically aggressive tumours and appropriately select patients for adjuvant systemic or targeted therapies [12].

The role of CCND1 is known as a key player molecule in control of the shift of cell cycle from phase G1 to S phase by pRb mediation. CCND1/Cyclin-Dependent Kinase (CDK) 4–6 complexes initiate the phosphorylation of pRb and cyclin E/CDK2 complex completes the procedure in late G1 phase. Alterations in cyclin and CDK expression result in increased cell proliferation and contribute to malignancy [15]. CCND1 protein stimulated cellular proliferation and contributes to oncogenesis [16]. CCND1 gene is disrupted in the cancer cell genome usually by the process of gene amplification or chromosome translocation which may be involved in malignancy [17]. In humans over-expression
of CCND1 is seen in many tumours including colorectal cancers [12].

Although lots of studies have been performed on CCND1 expression in CRC, they seem to be ending up with conflicting conclusions. Some found that CCND1 is of prognostic importance in CRC. However, they did find association between CCND1 and survival. The findings were also conflicting regarding which is favourable low or high CCND1 [1,4,18–22]. Since all these studies on CCND1 have used immunostaining the variability in results could be due to the use different anti-CCND1 antibody clones and using different cut off points for immunostaining scoring. Other factors that differ among these studies are the number of cases, and techniques used. However, the results in the present study are in concordance with a previous study [20] supporting the observations that there seems to be no statistically significant correlation between CCND1 expression and overall survival probability or clinicopathological features.

Ogino et al. [22] examined the relation between CCND1 expression and survival of patients in stage I to IV CRC. They found that CCND1 overexpression was independent of clinicopathological features and other related molecular variables such as p53, p21, p27, KRAS, BRAF, LINE-1 methylation, MSI, and the CIMP. All of these characteristics are potential confounders in analysis of tumoral CCND1 status and patient survival. They concluded that CCND1 expression in colon cancer is associated with superior prognosis [22]. In addition, CCND1 expression in colon cancer is related with microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), and BRAF mutation [23].

Studies have suggested strong association of CCND1 expression with prolonged survival among male with CRC [19] adding further momentum to the existing evidence that CRC is a hormone-dependent cancer, for which prognostic and treatment predictive molecular biomarkers should be evaluated based on patients gender [19].

Zhang et al. [24] reported that knockdown of paired box (PAX2), a transcription factor, inhibits the activity of AP-1, a transcription factor that induces CCND1 expression, implying that PAX2 induces CCND1 through AP-1 (a transcription factor) in CRC. PAX2 plays a critical role in embryogenesis. When aberrantly expressed in adult tissues, it generally exhibits oncogenic properties [24]. The mRNA cap-binding protein, eukaryotic initiation factor 4E (elf4E) is critical in translation initiation due to its limiting amount in the cell. elf4E levels were moderately correlated with VEGF and CCND1 in colon cancer supporting the role for elf4E in translational regulation of proteins related to angiogenesis and growth [25]. Myklebust et al. [4] investigated the roles of CCND1a and CCND1b, as prognostic markers in CRC in a cohort. In CRC, combined stage 1 and 2 in addition to stage III, CCND1a nuclear overexpression was found to be a predictive marker for benefit from 5-fluorouracil and levamisole comparable to surgery. Contrary, low nuclear immunoexpression of CCND1a has no effect on treatment outcome [4]. CCND1b has neither prognostic nor predictive association in CRC [4,25].

Limitations of the current study include: TMA uses only a small part of a tissue specimen that may not be represent the actual gene or protein nature and distribution within a tumour which is also prone to exhibit heterogeneous territorial staining patterns [3,12,26]. Regarding using immunohistochemistry to highlight CCND1, although the method is sensitive, results are not quantitative and there are no standardised scoring systems or uniformly accepted threshold for positivity which are major limitations to interpretations.

5. Conclusion

Our study indicates that CCND1 immunoexpression cannot be used as a predictor of survival in CRC. It also shows no significant correlation with clinicopathological features except with lymphovascular invasion. However, further validation studies for the prognostic role of CCND1 in CRC are required clinically.

Acknowledgements

This work was supported by Ministry of Higher Education and King Abdulaziz City for Science and Technology (KACST) grant 11-BIO1524-03 and the Scientific Chair for Colorectal Cancer, King Abdulaziz University, Jeddah, Saudi Arabia.

References

[1] Merrelsstein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, et al. Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 2005;93(3):338–45.
[2] Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007;6:24.
[3] Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 2005;58(5):509–14.
[4] Myklebust M, Li Z, Tran TH, Rui H, Knudsen H, Elsaele E, et al. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer 2012;107:1684–91.

[5] Hult J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24(17):7598–611.

[6] Li Z, Jiao X, Wang C, Shirley LA, Elsaele H, Dahl O, et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010;70(21):8802–11.

[7] Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011;474(7350):230–4.

[8] Avninder S, Ylaya K, Hewitt SM. Tissue microarray: a simple technology that has revolutionized research in pathology. J Postgrad Med 2008;54(2):158–62.

[9] Packeisen J, Korschning E, Herbst H, Boecker W, Buerger H. Demystified ... tissue microarray technology. Mol Pathol 2003;56(4):198–204.

[10] Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K, et al. Immunohistochemical expressions of Ki-67, cyclin D1, β-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomark Prev 2006;15(9):1719.

[11] Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10(7):657–62.

[12] Chen WC, Lin MS, Zhang BF, Fang J, Zhou Q, Hu Y, et al. Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray. World J Gastroenterol 2007;13(5):699–708.

[13] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9–29.

[14] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.

[15] Yasui M, Yamamoto H, Ngan CY, DaMindsay B, Sugita Y, Fukunaga H, et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 2006;12(15):4720–9.

[16] Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004;10(15):5168–77.

[17] Balcerzak E, Pasz-Walczak G, Kumor P, Panczyk M, Kordek R, Wierzbicki R, et al. Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur J Surg Oncol 2005;31(7):721–6.

[18] Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004;9(1):95–104.

[19] Wangeford S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirström K. Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ 2011;2:10.

[20] Ioachim E. Expression patterns of cyclins D1, E and cyclin dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinomas: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract 2008;62(11):1736–43.

[21] Kourakis G, Theocharis S, Vanvakas P, Vagianos C, Clinaou A, Giaginis C, et al. Cyclin D1 and RB protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol 2006;4:5.

[22] Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009;15(13):4431–8.

[23] Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kikrner GJ, et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008;53(3):588–98.

[24] Zhang HS, Yan B, Li XB, Fan L, Zhang YF, Wu GH, et al. PAX2 protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer cells. J Biol Chem 2012;287(53):44164–72.

[25] Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tissue microarray. Oncol Rep 2007;17(2):281–7.

[26] Fernebro E, Distor M, Bendahl PO, Ferno M, Nilbert M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 2002;126(6):702–5.